Document is current
Any future updates will be listed below
-
Authors
Wessel, Remziye E. https://orcid.org/0000-0002-8596-4700
Tong, Xin https://orcid.org/0009-0007-4784-1818
Bhattacharya, Allison
Burrell, Allison R. https://orcid.org/0000-0002-2271-8430
Spranger, Sara https://orcid.org/0009-0004-5845-2373
Morrow, Ardythe L. https://orcid.org/0000-0002-1126-4525
Payne, Daniel C. https://orcid.org/0000-0002-5871-911X
Ackerman, Margaret E. https://orcid.org/0000-0002-4253-3476
Alter, Galit
Staat, Mary A. https://orcid.org/0000-0003-1788-8037
Lauffenburger, Douglas A. https://orcid.org/0000-0002-0050-989X
-
Funding
Funding for this research was provided by:
National Institutes of Health (U01-A1144673)
National Institutes of Health (U19-AI167899)
Open Philanthropy/Good Ventures Foundation
- License Information
-
More Information
Article History
Received: 9 March 2026
Accepted: 22 July 2026
First Online: 31 July 2026
Ethics
Competing interests: G.A. was an employee of Moderna Therapeutics and holds equity in Leyden Labs and Systems Seromyx. M.A.S. received funding from the NIH and Good Ventures for this study, received research funding from the CDC, Pfizer, Merck, and Cepheid, has received funding as a consultant for Merck and an honorarium from UpToDate for infectious disease topics. D.C.P. reports institutional support from Bavarian-Nordic, Inc. and consulting from Merck and Moderna. M.E.A. reports grant support from Be Bio and Moderna unrelated to influenza vaccines. The remaining authors declare no competing interests.
